Biogen Earnings Call: Solid 2025, Cautious 2026 Outlook

Biogen Inc. ((BIIB)) has held its Q4 earnings call. Read on for the main highlights of the call.

Biogen Balances Solid 2025 Performance With Cautious 2026 Outlook

Biogen’s latest earnings call struck a tone of guarded optimism. Management highlighted better‑than‑expected earnings, strong cash generation, and clear traction from newer “growth” products and pipeline advances. At the same time, they acknowledged that overall revenue is likely to decline in 2026 as legacy multiple sclerosis (MS) therapies face intensifying generic and biosimilar competition, and as reimbursement and inventory dynamics add noise to near‑term trends. The message to investors was that Biogen is in a transition phase—using its healthy balance sheet to invest in launches and R&D while managing pressure on its older franchises.

Strong Earnings, Cash Generation and Balance Sheet

Biogen delivered robust profitability and cash flow in 2025, signaling operational discipline despite its shifting revenue mix. Full‑year 2025 non‑GAAP diluted EPS came in at $15.28, above expectations, with Q4 non‑GAAP EPS of $1.99. Total revenue reached $9.9 billion, up about 2% from 2024, and free cash flow totaled a solid $2.1 billion. The company ended the year with $4.2 billion in cash and marketable securities and net debt of $2.0 billion, giving it meaningful financial flexibility for business development and pipeline investment. This balance sheet strength underpins Biogen’s ability to absorb legacy product erosion while funding its next wave of launches.

Growth Products Provide Increasing Momentum

Biogen’s recently launched “growth” portfolio is emerging as a more meaningful driver of the business. In 2025, growth products generated $3.3 billion in revenue, including more than $800 million in Q4 alone. Management emphasized strong year‑over‑year gains for this cohort, with newer launches since 2023—Lekembi, Skyclaris, Xerxuve, and Calcadi—now collectively surpassing $1 billion in annual sales. This expanding contribution from newer products is critical to offsetting structural declines in older MS treatments and supports the company’s long‑term transition narrative.

Market Leadership in Anti‑Amyloid Alzheimer’s Therapy

Lekembi continues to be a centerpiece of Biogen’s growth story, reinforcing the company’s ambition in Alzheimer’s disease. The drug has secured more than 60% share of the anti‑amyloid therapy market, and management noted persistency after plaque removal at roughly 70%, suggesting durable patient engagement. Importantly, the subcutaneous “iClick” induction formulation has received priority review, with a regulatory decision expected in May 2026. If approved, this more convenient administration route could ease the infusion burden, broaden patient access, and further solidify Lekembi’s leadership position in a key long‑term market.

Commercial Wins Across Key Products

Beyond Lekembi, Biogen reported several notable commercial successes that underscore the breadth of its growth portfolio. Xerxuve more than doubled sales in 2025, while Skyclaris posted Q4 global revenue of $133 million, up around 30% year over year, with $89 million coming from the U.S. Management highlighted a step‑change in Akembi end‑market sales, which reached about $134 million in Q4, a dramatic increase versus prior quarters. VUMERITY, part of the MS portfolio but still in growth mode, delivered $747 million in 2025, up 19% year over year. These performances illustrate that Biogen’s newer and differentiated assets are gaining traction even as older products decline.

Pipeline Expansion and Regulatory Momentum

The company significantly broadened its pipeline in 2025, positioning itself for potential future launches across several disease areas. Lidifolumab (litifolumab) received FDA Breakthrough Therapy designation for cutaneous lupus, and the pivotal TOPAZ‑2 readout is expected by the end of 2026. Biogen is also advancing BIB080, a tau‑targeting program with phase 2 data anticipated mid‑year, and expects a regulatory decision on high‑dose SPINRAZA in April 2026. In addition, the BTK degrader BIG145 entered phase 1 testing in healthy volunteers. This combination of late‑stage readouts and early‑stage entries reflects a deliberate effort to build a multi‑year growth pipeline, though outcomes remain a key swing factor for the stock.

Strategic Deals and Acquisitions Support Long‑Term Strategy

Biogen continued to lean on business development to strengthen its platform and future product lineup. The company announced the acquisition of Alcion Therapeutics, designed to enhance delivery options for intrathecal therapies such as SPINRAZA and potentially improve treatment convenience. It also entered new collaborations with Vanqua and Dara Therapeutics in Q4, broadening its portfolio and research options. While these deals come with upfront costs that weigh on near‑term GAAP results, management framed them as critical investments to diversify revenues and build sustainable long‑term growth.

Guidance Points to a 2026 Revenue Dip

For 2026, Biogen guided investors to a mid single‑digit decline in total revenue versus 2025’s $9.9 billion, underscoring that the transition away from legacy MS dependence is still in progress. Non‑GAAP diluted EPS is expected in the $15.25–$16.25 range, essentially flat to modestly higher than 2025’s $15.28, implying margin discipline and cost control despite the top‑line pressure. Management expects MS revenue excluding VUMERITY to fall by a mid‑teens percentage in 2026, reflecting ongoing erosion in older products. Contract manufacturing revenue is forecast at about $300 million per half, or roughly $600 million for the year, suggesting little growth from that segment. Gross margins are projected to be roughly consistent with 2025, and core operating expenses should remain broadly flat, though Q1 2026 is expected to show about 10% higher year‑over‑year spending as launch and pipeline investments continue.

Legacy MS Franchise Under Intensifying Competitive Pressure

Biogen’s traditional revenue base in multiple sclerosis continues to face serious headwinds from generics and biosimilars. TECFIDERA is seeing accelerating generic erosion in Europe, a trend management expects to persist through 2026. Meanwhile, the introduction of a TYSABRI biosimilar in the EU is adding further pressure on this cornerstone product line. These competitive dynamics are a key reason for the projected mid‑teens decline in MS revenue (excluding VUMERITY) next year, and they highlight the urgency of ramping newer therapies to stabilize the overall revenue base.

One‑Time Charges and R&D Investment Weigh on GAAP Results

The quarter’s GAAP results were notably affected by one‑time items tied to Biogen’s business development and legal activities. Q4 included $222 million in in‑process R&D (IPR&D) charges from recent deals, alongside roughly $180 million of one‑time GAAP operating charges related to litigation and other matters. Management quantified the impact of Q4 business development transactions at $1.26 per share of EPS. While these charges obscure underlying profitability, they also reflect the company’s strategy of reinvesting current cash flows into future growth opportunities, albeit with near‑term earnings volatility.

SPINRAZA and Other Franchise Headwinds

SPINRAZA, once a major growth engine, is holding up but no longer expanding. Q4 global revenue was $356 million, and full‑year sales declined about 2% year over year, pressured by competition and the timing of shipments, particularly outside the U.S. Management characterized the brand as resilient but acknowledged ongoing challenges. These headwinds, combined with legacy MS erosion, reinforce the importance of pipeline progress and successful execution around new launches to maintain overall company momentum.

Reimbursement, Inventory and Timing Add Near‑Term Noise

Biogen also flagged several technical factors that could distort near‑term revenue trends, especially for investors watching quarter‑to‑quarter numbers closely. The subcutaneous iClick induction for Lekembi is currently reimbursed via Part D formulary exemptions, with full Part D coverage not expected until early 2027, which may limit the pace of adoption despite strong fundamentals. Skyclaris’ Q4 ex‑U.S. performance included around $12 million of net pricing adjustments, while U.S. sales benefited from roughly $9 million of favorable inventory dynamics that management expects to unwind in Q1 2026. VUMERITY’s Q4 U.S. revenue was also negatively affected by shipment timing. These factors introduce short‑term noise but do not necessarily reflect underlying demand trends.

Limited Near‑Term Upside From Manufacturing

Investors looking for diversification from Biogen’s contract manufacturing business should temper expectations in the near term. Management guided contract manufacturing revenue to about $300 million in each half of 2026, or approximately $600 million for the year, which implies flat performance rather than a new growth leg. While this segment provides a stable revenue contribution, it is unlikely to materially offset the expected decline in legacy MS revenue or drive earnings expansion on its own.

Pipeline Readouts Highlight Execution Risk

Biogen’s long‑term equity story hinges heavily on upcoming clinical and regulatory milestones, which management acknowledged carry meaningful execution risk. Key registrational readouts include litifolumab in systemic lupus erythematosus, phase 2 data for the tau‑targeting BIB080, and selzartamab results in antibody‑mediated rejection. Positive data could pave the way for important launches around 2028, but the timing and ultimate success of these programs remain uncertain. For investors, this creates a binary element to the medium‑term outlook: strong data could justify a higher growth multiple, while setbacks would increase reliance on the existing portfolio.

Forward‑Looking Guidance: Transition Year Before Potential Reacceleration

Biogen’s 2026 guidance underscores that the company is in a transition year, using consistent earnings and strong cash generation to bridge toward a potentially more diversified future. With total revenue expected to decline by a mid single‑digit percentage and non‑GAAP EPS essentially flat to slightly higher, management is signaling disciplined cost control even as it leans into launch and R&D spending. MS revenue excluding VUMERITY is set to fall by a mid‑teens percentage, contract manufacturing revenue should remain steady near $600 million, and gross margins and core operating expenses are projected broadly in line with 2025 levels. The company’s message is that near‑term growth will be limited, but the combination of growth products, advancing pipeline assets, and strategic deal‑making could set the stage for renewed expansion later in the decade.

In summary, Biogen’s earnings call painted a picture of a company managing a complex but deliberate transition. Earnings, cash flow, and the balance sheet remain solid, and newer products like Lekembi, Skyclaris, Xerxuve, and VUMERITY are gaining momentum. However, intensifying pressure on the legacy MS franchise, near‑term revenue headwinds, one‑off charges, and clinical execution risk temper the story. For investors, the key takeaway is that Biogen is trading short‑term revenue softness for a longer‑term growth option set, with upcoming regulatory decisions and pivotal trial readouts likely to be decisive catalysts for the stock over the next several years.